Physician profile
Jennifer Ryan
NPI 1306377577
$1,534.32
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $869 · 2022: $586 · 2023: $30.43 · 2024: $48.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $78.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $78.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $378.08 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $105.14 | 2021-2022 | |
| Dexcom, INC. | $105.04 | 2022-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $98.75 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.24 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.16 | 2021-2022 | |
| Lilly USA, LLC | $70.73 | 2021-2022 | |
| Amarin Pharma, INC. | $49.44 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $48.31 | 2024 | Assure Wcd |
| Abbott Laboratories | $39.00 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $36.19 | 2021-2022 | |
| Mylan Specialty L.P. | $32.33 | 2021 | |
| Collegium Pharmaceutical, INC. | $31.94 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $31.16 | 2021 | |
| Arbor Pharmaceuticals, INC. | $29.77 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $28.99 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.57 | 2022 | |
| Merck Sharp & Dohme LLC | $25.19 | 2021 | |
| Glaxosmithkline, LLC. | $25.10 | 2021 | |
| Corcept Therapeutics | $24.86 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $24.71 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.04 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.89 | 2021 | |
| Eisai INC. | $17.73 | 2021 | |
| Grt US Holding, INC. | $15.94 | 2022 | |
| Esperion Therapeutics, INC. | $15.05 | 2021 | |
| Medtronic, INC. | $13.73 | 2021 | |
| Sanofi Pasteur INC. | $13.22 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.98 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.